dacarbazine + temozolomide + paclitaxel + carboplatin + cisplatin

This combination refers to the investigator-selected chemotherapy (ISC) regimen used as the active control arm in clinical trials sponsored by Suzhou BlueHorse Therapeutics, specifically for the treatment of advanced melanoma. The regimen typically consists of standard-of-care cytotoxic agents, including the alkylating agents dacarbazine and temozolomide, the microtubule-stabilizing taxane paclitaxel, and the platinum-based DNA crosslinking agents carboplatin and cisplatin. These agents are administered to patients who have progressed on or failed prior standard therapies, such as immune checkpoint inhibitors or targeted therapies. In the context of Suzhou BlueHorse's Phase II trial for LM103 (autologous tumor-infiltrating lymphocytes), this chemotherapy serves as the comparator for evaluating the efficacy and safety of cell-based immunotherapy. The specific choice of agent(s) within this list is determined by the investigator based on patient history and clinical guidelines.

Other names

Investigator's choice chemotherapyISC